Rapid Malaria Pf/Pv Antigen Card Test Suppliers & Bulk Manufacturers
Available Forms: Test Kits
Available Strengths: 1 test/kit
Reference Brands: SD BIOLINE Malaria (USA), CareStart Malaria HRP2/pLDH (USA/EU), Meril Malaria Pf/Pv Test (India)
Category:
Rapid Test Kits
Malaria Pf/Pv Antigen Rapid Test (RDT) performs as a better sensor and discriminator of malarial parasites and their species and appears to be an acceptable tool for diagnosis of malaria in symptomatic patient.
Rapid Malaria PF/PV Antigen Card Test is available in Test Kits
and strengths such as 1 test/kit.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Rapid Malaria PF/PV Antigen Card Test is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Rapid Malaria PF/PV Antigen Card Test can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
The ICT Malaria P.f./P.v. test is a rapid immunochromatographic assay designed for the qualitative detection of malaria infections in human blood. Manufactured in a convenient test card format, it provides quick and reliable results, making it suitable for point-of-care and field use, especially in resource-limited settings. The test specifically detects histidine-rich protein 2 (HRP2), an antigen produced by Plasmodium falciparum, along with a panmalarial antigen that is shared across multiple Plasmodium species.
This dual-detection capability allows the test to identify infections caused by both Plasmodium falciparum and Plasmodium vivax, the two most common malaria-causing parasites. Field studies have demonstrated its effectiveness in detecting P. vivax, expanding its diagnostic utility. While earlier findings suggested limitations in detecting P. malariae, emerging evidence indicates that the panmalarial antigen targeted by the test may also be expressed by this species, enhancing its potential diagnostic scope.
Overall, the ICT Malaria P.f./P.v. test serves as a valuable tool for rapid screening and early diagnosis, supporting timely treatment decisions and helping to control the spread of Malaria.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing